Hepatitis C News and Research

Latest Hepatitis C News and Research

Tacere Therapeutics submits TT-034 clinical trial application to Recombinant DNA Advisory Committee

Tacere Therapeutics submits TT-034 clinical trial application to Recombinant DNA Advisory Committee

18 Apr 2013
Flunisyn Phase 2a trial data shows positive results in elderly population

Flunisyn Phase 2a trial data shows positive results in elderly population

17 Apr 2013
Benitec to conduct phase I/II clinical trial of TT-034 in patients with HCV in UCSD site

Benitec to conduct phase I/II clinical trial of TT-034 in patients with HCV in UCSD site

16 Apr 2013
Study reveals inner workings of master regulator that controls diverse functions

Study reveals inner workings of master regulator that controls diverse functions

12 Apr 2013
New approaches to treat persistent viral infections like HIV and hepatitis C

New approaches to treat persistent viral infections like HIV and hepatitis C

12 Apr 2013
New research shows safety can be improved for people participating in medical experiments

New research shows safety can be improved for people participating in medical experiments

12 Apr 2013
MKK4 gene could be a promising therapeutic target for liver disease, study reveals

MKK4 gene could be a promising therapeutic target for liver disease, study reveals

12 Apr 2013
New data on Merck’s VICTRELIS for chronic HCV to be presented at EASL annual meeting

New data on Merck’s VICTRELIS for chronic HCV to be presented at EASL annual meeting

11 Apr 2013
Nev. jury orders HMO to pay $500M in punitive damages after hepatitis C outbreak

Nev. jury orders HMO to pay $500M in punitive damages after hepatitis C outbreak

11 Apr 2013
Johns Hopkins scientists create Web-based tool to help patients decide on kidney transplantation

Johns Hopkins scientists create Web-based tool to help patients decide on kidney transplantation

11 Apr 2013
First Edition: April 10, 2013

First Edition: April 10, 2013

10 Apr 2013
Boehringer Ingelheim's STARTVerso 1 Phase 3 hepatitis C data to be presented at EASL Congress

Boehringer Ingelheim's STARTVerso 1 Phase 3 hepatitis C data to be presented at EASL Congress

10 Apr 2013
Newly discovered mouse viruses can pave the way for future progress in hepatitis research

Newly discovered mouse viruses can pave the way for future progress in hepatitis research

9 Apr 2013
Clinical data of two Transgene products to be presented at EASL Conference

Clinical data of two Transgene products to be presented at EASL Conference

9 Apr 2013
Gilead Sciences submits sofosbuvir NDA to FDA for treatment of chronic HCV infection

Gilead Sciences submits sofosbuvir NDA to FDA for treatment of chronic HCV infection

9 Apr 2013
Phase 3 study results of simeprevir in hepatitis C patients to be presented at EASL Congress

Phase 3 study results of simeprevir in hepatitis C patients to be presented at EASL Congress

8 Apr 2013
Abstracts on Bristol-Myers Squibb's research in liver disease accepted for presentation

Abstracts on Bristol-Myers Squibb's research in liver disease accepted for presentation

8 Apr 2013
Nektar Therapeutics presents positive results for NKTR-214 at AACR Annual Meeting

Nektar Therapeutics presents positive results for NKTR-214 at AACR Annual Meeting

8 Apr 2013
National Jewish Health researchers unravel mystery of adjuvants

National Jewish Health researchers unravel mystery of adjuvants

8 Apr 2013
Liver transplants worth risk for people who have genetic liver conditions, study finds

Liver transplants worth risk for people who have genetic liver conditions, study finds

6 Apr 2013

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback